Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 50% after announcing the acquisition of Polynoma and a $25 ...
TransCode Therapeutics ( ($RNAZ) ) has issued an update. On October 14, 2025, TransCode Therapeutics announced the completion of its Phase 1a ...
BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...
TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA. The precursor may be ...
CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move ...
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday. Separately, ...
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Friday. Separately, HC Wainwright ...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today ...
Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. Our government trade tracker caught Pelosi’s 169% AI winner.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback